EP4287853A1 - Composition liquide vaporisable pour cigarette electronique renfermant au moins de la nicotine et un cannabinoïde - Google Patents
Composition liquide vaporisable pour cigarette electronique renfermant au moins de la nicotine et un cannabinoïdeInfo
- Publication number
- EP4287853A1 EP4287853A1 EP22708196.5A EP22708196A EP4287853A1 EP 4287853 A1 EP4287853 A1 EP 4287853A1 EP 22708196 A EP22708196 A EP 22708196A EP 4287853 A1 EP4287853 A1 EP 4287853A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nicotine
- advantageously
- cbd
- composition
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 142
- 229960002715 nicotine Drugs 0.000 title claims abstract description 131
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 239000003571 electronic cigarette Substances 0.000 title claims abstract description 51
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 33
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 100
- 239000007788 liquid Substances 0.000 title claims description 45
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 122
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 122
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 122
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 122
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 122
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 100
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 59
- 235000013311 vegetables Nutrition 0.000 claims description 35
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 32
- 235000011187 glycerol Nutrition 0.000 claims description 29
- 230000000391 smoking effect Effects 0.000 claims description 20
- 150000002009 diols Chemical class 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000004090 dissolution Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- 150000003505 terpenes Chemical class 0.000 claims description 8
- 235000007586 terpenes Nutrition 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 229940065144 cannabinoids Drugs 0.000 claims description 5
- 208000035824 paresthesia Diseases 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 abstract description 18
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 18
- 229960004063 propylene glycol Drugs 0.000 description 30
- 235000013772 propylene glycol Nutrition 0.000 description 30
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 25
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 210000003800 pharynx Anatomy 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000002585 base Substances 0.000 description 16
- 229960004242 dronabinol Drugs 0.000 description 15
- 239000013078 crystal Substances 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 235000019504 cigarettes Nutrition 0.000 description 13
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000779 smoke Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 8
- 244000025254 Cannabis sativa Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000005586 smoking cessation Effects 0.000 description 6
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 5
- 206010012335 Dependence Diseases 0.000 description 5
- 208000025569 Tobacco Use disease Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000009120 camo Nutrition 0.000 description 5
- 235000005607 chanvre indien Nutrition 0.000 description 5
- 239000011487 hemp Substances 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 230000008016 vaporization Effects 0.000 description 5
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 4
- 206010057852 Nicotine dependence Diseases 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000009834 vaporization Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000019568 aromas Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 101100059509 Mus musculus Ccs gene Proteins 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003348 petrochemical agent Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
- A24B15/303—Plant extracts other than tobacco
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
Definitions
- the present invention relates to the combination of a cannabinoid and nicotine, and advantageously of at least one diol, for use in the conduct of smoking, nicotine and vapor withdrawal.
- This combination which may additionally contain an acid, flavorings and/or terpenes, is contained in a vaporizable liquid composition for an electronic cigarette.
- the electronic cigarette is an existing and democratized market since 2010 in France and around the world. It is now a market regulated and framed by the tobacco directive, although its use is based on an alternative to tobacco linked to healthier and less harmful consumption than that of conventional tobacco, as has been demonstrated in numerous studies ( https://helveticvape.ch/le-rapport-de-public-health-england).
- an electronic cigarette is an electromechanical or electronic device generating an aerosol intended to be inhaled. It produces “vapor” or “artificial smoke” visually resembling the smoke produced by burning tobacco. This vapor can be flavored with different kinds of aromas: blond tobacco, brown, fruit, mint, gourmet flavors, . . . It may or may not contain nicotine.
- the electronic cigarette is composed of three main elements:
- the tank is the part that contains the e-liquid. It is most often cylindrical in shape, made of polyethylene, glass or stainless metal, but can also be in the form of a cartridge.
- the tank has two openings: an air inlet and a steam outlet.
- the outlet is usually equipped with an interchangeable mouthpiece, commonly referred to as a "drip tip" in the field.
- composition of the e-liquid which is used in electronic cigarettes most often includes the following elements: propylene glycol representing 50% to 80% by weight of the e-liquid; vegetable glycerin representing 20% to 50% by weight of the e-liquid; nicotine at a concentration ranging from 0 mg/ml to 20 mg/ml;
- Vegetable glycerin makes it possible to have a rounder vape (i.e. the action of vaping) in the mouth, lessens this irritation during inhalation, with a strong visible vapor emerging during exhalation and reminiscent of the classic cigarette.
- glycerin which is a viscous compound, does not favor the rendering of the aroma and causes certain difficulties during vaporization when it is used in large quantities, forcing use of the electronic cigarette at higher temperatures to allow to the product to vaporize and thus favoring, during the degradation of the product, the appearance of undesirable by-products such as acrolein.
- Cannabidiol is a cannabinoid, namely a group of chemicals that activate cannabinoid receptors found in the human body. It is one of the molecules extracted from the Cannabis sativa plant (or cultivated hemp). Its many virtues therapeutics have been proven, as has its non-psychoactive effect. It is currently used in different forms (www.cbd-france.fr), such as oil, food, creams, crystals and now in e-liquids vaporized using electronic cigarettes.
- composition of e-liquids containing CBD is as follows: cannabidiol at 0 mg to 1000 mg per 10 ml in the form of oil or pure crystals, i.e. a CBD concentration ranging from 0 mg/ml to 100 mg/ml; propylene glycol representing 80% and up to 100% by weight of the e-liquid; vegetable glycerin representing from 0% to 20% by weight of the e-liquid;
- CBD crystals are difficult to dissolve in vegetable glycerin, because they are too viscous, which leads manufacturers to use a composition containing 80% propylene glycol and 20% vegetable glycerin in order to dissolve them more easily.
- CBD crystals As mentioned previously, propylene glycol presents a more fluid basic solution than that of vegetable glycerin and allows better dissolution and fixation of CBD like aromas.
- propanediol with cannabidiol overcomes these difficulties.
- Propanediol is more fluid than propylene glycol and is an organic solvent allowing better dissolution of CBD, including at high concentrations of up to 1500 mg per 10 ml (150 mg/ml).
- the CBD can be dissolved in a base composed of 100% propanediol and free of any other product.
- the dissolution of the CBD is then greater, thus improving the bioavailability of the product by inhalation, the composition then being able to be inhaled as it is.
- propanediol associated with CBD also makes it possible to reduce the fouling of resistors and equipment.
- MAOIs monoamine oxidase inhibitors
- the invention relates to the combination of a cannabinoid and nicotine for use in the conduct of withdrawal, advantageously smoking, nicotine and/or vapology, using an electronic cigarette.
- this combination is contained or enclosed in a vaporizable liquid composition for an electronic cigarette, which may contain other ingredients detailed below.
- CBD cannabidiol
- This molecule can come from the Cannabis sativa plant (https://dumas.ccsd.cnrs.fr/dumas-00983072/document), or hemp, a plant derivative with a very low THC content, or hops.
- the CBD is in the form of pure crystals, derived from authorized varieties and parts of plants and making it possible to exclude any trace of THC in the finished product, thus meeting legal standards, in particular in France.
- CBD is not classified as a narcotic in France if the cannabinoid is extracted from authorized hemp varieties with a THC content of less than 0.3% and if the finished product after processing is free of any trace of THC (http://www.drogues.gouv.fr/ actualites/cannabidiol-cbd-point-legislation).
- CBD can be used in different forms such as pure crystals, powder, distillate (CBD concentrate containing other cannabinoids) or oil.
- the CBD comes from a totally organic culture.
- a vaporizable liquid composition according to the invention advantageously contains a solvent, even more advantageously a diol such as propylene glycol or propanediol.
- a solvent even more advantageously a diol such as propylene glycol or propanediol.
- the most suitable and preferred solvent for transporting these two molecules is propanediol, combined or not with advantageously vegetable glycerin.
- Propanediol can be vegetable or synthetic and allows better dissolution of cannabidiol (CBD). Propanediol can thus be derived from vegetable raw materials and obtained by fermentation of glycerol via a biological process that respects the environment.
- a vaporizable liquid composition comprises a cannabinoid, advantageously cannabidiol (CBD), nicotine, advantageously a nicotine salt, and a diol, advantageously propanediol.
- CBD cannabidiol
- composition according to the invention may comprise at least one of the following additives: advantageously vegetable glycerin, propylene glycol, flavorings, terpenes, water and/or an alcohol such as ethanol.
- composition used may or may not contain propylene glycol, whether synthetic or of vegetable origin, that is to say obtained from vegetable raw materials.
- Propylene glycol is obtained from the reaction of propylene oxide with water to form monopropylene glycol (MPG), or by plant production using biosourced monopropylene glycol.
- Propylene glycol, synthetic or of vegetable origin can thus represent from 0% to 90% by weight of the composition, preferably from 0% to 70% or even from 0% to 50%.
- the composition according to the invention is free of propylene glycol.
- synthetic propylene glycol is very irritating and its use in a high proportion in the composition, necessary to facilitate the dissolution of CBD, makes it unsuitable for use in an e-liquid of electronic cigarette.
- the composition may or may not contain glycerin, advantageously of vegetable origin. According to a preferred embodiment of the invention, the composition contains little glycerin, advantageously of plant origin. Indeed and as mentioned above, its viscosity hinders the dissolution of CBD, thus reducing its bioavailability and therefore its effects. Its high viscosity also requires a higher heating temperature which, during the degradation of the product, can lead to the appearance of unsuitable impurities during inhalation, such as acrolein which is toxic.
- the composition can also contain aromas and/or terpenes to give an aromatic note to the composition.
- the concentration of aroma(s) and/or terpene(s) can be from 0% to 20% by weight, preferably from 0% to 15% by weight, more preferably from 0% to 10% by weight of the composition .
- terpenes associated with other cannabinoids can provide an entourage effect and therefore enhance the effects of CBD, a phenomenon accentuated by its greater bioavailability due to its association with propanediol.
- composition used may or may not also contain alcohol such as ethanol and/or water and/or at least one colorant.
- diol advantageously propanediol
- glycerin preferably vegetable glycerin
- it corresponds to one of the compositions described in point 1 of the embodiment examples, in particular to a composition according to stages #2 to #5.
- such a combination in particular of CBD, propanediol, nicotine or even lactic acid, or composition allows:
- the invention relates to a kit intended for smoking, nicotine and/or vapor withdrawal comprising at least one composition as defined above.
- such a kit comprises at least two compositions as defined above.
- the at least two compositions have different nicotine concentrations.
- the at least two compositions have different cannabinoid concentrations.
- the sum of the nicotine and cannabinoid concentrations is equal in each of the compositions.
- Such a process comprises taking compositions as defined above in stages, comprising decreasing concentrations of nicotine, advantageously ranging from 20 mg/ml to 5 mg/ml, even more advantageously 20, 15, 10 and 5 mg/ml .
- compositions used in the context of weaning comprise increasing cannabinoid concentrations, advantageously ranging from 5 mg/ml to 20 mg/ml, even more advantageously 5, 10, 15 and 20 mg/ml, so as to compensate for the decrease in nicotine concentration.
- the invention relates to:
- an electronic cigarette liquid composition containing at least one diol as well as nicotine and at least one cannabinoid compound except delta-9 tetrahydrocannabinol (THC) in the conduct of smoking and nicotine withdrawal;
- an electronic cigarette liquid composition containing at least one diol as well as nicotine and at least one cannabinoid compound except delta-9 tetrahydrocannabinol (THC) for its use in the conduct of smoking and nicotine withdrawal;
- THC delta-9 tetrahydrocannabinol
- composition containing at least one diol preferably 1.3 propanediol with nicotine base or nicotine salt, that is to say nicotine base to which an acid and cannabidiol are added (CBD) preferably in the form of pure crystals derived from authorized varieties and parts of plants and making it possible to exclude any trace of delta-9 tetrahydrocannabinol (THC) in the finished product, with or without vegetable glycerin to improve the dissolution and bioavailability of CBD by inhalation and maximizing CBD-nicotine interactions;
- CBD cannabidiol
- THC delta-9 tetrahydrocannabinol
- diol preferably 1.3 propanediol, nicotine base or nicotine salt
- cannabidiol preferably in the form of pure crystals derived from authorized varieties and parts of plants and making it possible to exclude any trace of delta-9 tetrahydrocannabinol (THC) in the finished product, allowing less fouling of the equipment;
- THC delta-9 tetrahydrocannabinol
- compositions can be packaged in glass or plastic bottles (for example PET), generally with a volume of 10 ml, with a tip making it possible to fill an electronic cigarette without losses.
- compositions can also be packaged in sealed cartridges with an advantageous capacity of 2 ml, intended for electronic cigarettes of the "POD” type, making it possible to exclude any manipulation and any incorporation of foreign bodies into the composition by the end user. .
- Said bottles can be sold individually or in a kit comprising all or part of the bearings as defined in the table above.
- kit may also contain an electronic cigarette and instructions. These instructions may relate to the use of the electronic cigarette provided and/or the proposed withdrawal protocol, as detailed below. 2/ Sewing protocol
- compositions according to the invention contain at least nicotine base (to which an acid is added) and Cannabidiol (CBD), the aim of the withdrawal protocol being to reverse the two molecules for the benefit of the non-addictive (CBD ) in the conduct of smoking, nicotine and vapor withdrawal.
- CBD Cannabidiol
- This system of stages is intended to constitute the path leading to smoking, nicotine and vapological withdrawal with a treatment that will have a start date and an end date of use. It is recommended to use it for 3 to 6 months with the levels containing nicotine (levels 1 to 5), until use of the last level containing exclusively CBD, which can go up to 12 months for complete weaning from nicotine. tool, in this case the electronic cigarette.
- the principle of the system of stages in the conduct of a three-dimensional withdrawal aims to no longer worry about the right concentration of nicotine to choose, this work having already been done for smokers who can then focus only on their desire to quit smoking.
- the innovative method of the different levels, in particular the 6 levels defined below, associated with unique innovative formulations combining nicotine and CBD makes it possible to act on tobacco, nicotine and vapological dependence.
- the 6 levels defined below are to be respected and passed one after the other, without skipping steps. Only the starting level can vary according to the cigarette consumption of the smoker at the start of withdrawal.
- Step #1 Smoking cessation step
- the objective is to stay on the same starting level until you no longer smoke a single cigarette for a period of 15 consecutive days before being able to move on to the next level.
- Step #4 Nicotine withdrawal step
- Step #5 Nicotinic and vapor withdrawal step
- the CBD present compensates for the drop in nicotine, a hit is present and a sensation in the throat that persists a little more than in the previous levels contributes to less soliciting the use of the electronic cigarette.
- This level also begins to act on vapological dependence and habits related to gestures.
- the different stages defined serve as a benchmark to help in a weaning process but can be adapted to each profile of smokers.
- Nicotine remains a very important and essential tool for the purpose of quitting smoking. Nicotine is not carcinogenic, is not responsible for lung or other diseases related to smoking. It remains addictive, just like caffeine for example. It is an ally to cross the first stages of starting, the following stages allowing to act on the dependence on nicotine, then vapological for a complete weaning via the use of the composition and the association nicotine / CBD.
- the hit in the throat is very important for a smoker and in his participation in weaning.
- the hit of the said composition has been specially studied to best satisfy the smoker in his transition and differs from the hits that can be found in traditional e-liquids.
- the differentiated hit of the formulations has the particularity of being composed of a primary hit, which is felt at the level of the pharynx immediately when passing through the throat, and of a secondary hit, which extends more deeply after inhalation at the level of the larynx through the use of CBD.
- the combination of these two hits makes it possible to obtain a general hit that is as close as possible to inhaling a tobacco cigarette and thus promoting withdrawal.
- the primary hit will be less intense but the secondary hit will be prolonged, making it possible to reduce the desire to consume while being satiated at the level of the sensation of the passage in the throat.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2101196A FR3119517B1 (fr) | 2021-02-08 | 2021-02-08 | Composition vaporisable de liquide pour cigarette électronique renfermant au moins un diol, ainsi que de la nicotine et au moins un composé cannabinoïde exempt de delta-9-tétrahydrocannabinol. |
PCT/FR2022/050231 WO2022167773A1 (fr) | 2021-02-08 | 2022-02-08 | Composition liquide vaporisable pour cigarette electronique renfermant au moins de la nicotine et un cannabinoïde |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4287853A1 true EP4287853A1 (fr) | 2023-12-13 |
Family
ID=78332814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22708196.5A Pending EP4287853A1 (fr) | 2021-02-08 | 2022-02-08 | Composition liquide vaporisable pour cigarette electronique renfermant au moins de la nicotine et un cannabinoïde |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4287853A1 (fr) |
FR (1) | FR3119517B1 (fr) |
WO (1) | WO2022167773A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10639439B2 (en) * | 2013-01-30 | 2020-05-05 | Midwest Pharmaceuticals, Llc | Smokeless THC and administration method thereof |
FR3015186A1 (fr) * | 2014-03-11 | 2015-06-26 | Antoine Piccirilli | Utilisation d'une composition renfermant du 1,3-propanediol comme e-liquide |
CA2995970A1 (fr) * | 2017-02-22 | 2018-08-22 | Gene Bernaudo | Systeme de composition d'agent de melange destine aux cigarettes electroniques |
FR3078701A3 (fr) | 2018-02-09 | 2019-09-13 | Sebastien Ombe | Utilisation d'une composition renfermant du 1.3 propanediol ainsi que du cannabidiol comme liquide pour cigarette electronique. |
CN111000283A (zh) * | 2019-12-13 | 2020-04-14 | 武汉红金叶新材料科技有限公司 | 一种用于气溶胶装置的电子烟油及其制备方法和应用 |
-
2021
- 2021-02-08 FR FR2101196A patent/FR3119517B1/fr active Active
-
2022
- 2022-02-08 EP EP22708196.5A patent/EP4287853A1/fr active Pending
- 2022-02-08 WO PCT/FR2022/050231 patent/WO2022167773A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
FR3119517A1 (fr) | 2022-08-12 |
FR3119517B1 (fr) | 2024-04-12 |
WO2022167773A1 (fr) | 2022-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3107409B1 (fr) | Utilisation d'une composition renfermant du 1,3-propanediol comme e-liquide | |
CN106753787B (zh) | 一种烟用爆珠柠檬薄荷精油及其制备方法和应用 | |
US5845647A (en) | Tobacco and related products | |
CH702775B1 (fr) | Pastilles de gélatine douces contenant de la nicotine et procédé de préparation. | |
JP2017501714A (ja) | 電子タバコ用液体組成物 | |
CA3113041C (fr) | Produit en pochette pour l'application dans une cavite orale | |
US20160199299A1 (en) | Cannabis Infused Chewing Composition | |
FR3062303A1 (fr) | Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide | |
US20170367386A1 (en) | Terpene flavoring compositions | |
JP2022506094A (ja) | エアロゾル化可能な配合物 | |
JP2022506068A (ja) | エアロゾル化可能な配合物 | |
KR101257828B1 (ko) | 다마스콘 함유 금연보조제 조성물 | |
JP2022506076A (ja) | エアロゾル化された配合物 | |
US20110038915A1 (en) | Chewing Gum Formula for Enhancing Psycho-Spirituality | |
JP2022506067A (ja) | エアロゾル化可能な配合物 | |
FR3078702A3 (fr) | La présente invention concerne l’utilisation d’une composition de liquide pour cigarette électronique renfermant du 1.3 propanediol ainsi que du Cannabidiol (CBD). | |
EP4287853A1 (fr) | Composition liquide vaporisable pour cigarette electronique renfermant au moins de la nicotine et un cannabinoïde | |
WO2015067773A1 (fr) | Macérât de végétaux à base d'alcool éthylique | |
JP2021534812A (ja) | 組成物 | |
FR3089761A1 (fr) | Composition liquide de cigarette électronique | |
EP2888951A1 (fr) | Produit comprenant du kratom | |
US20120288450A1 (en) | Chewing gum formula for enhancing psycho-spirituality | |
CA2909750C (fr) | Composition pharmaceutique, dietetique ou alimentaire liquide ou semi-liquide depourvue d'amertume contenant un sel d'arginine | |
JP7102590B1 (ja) | 電子タバコ用リキッド、および電子タバコ用リキッドの製造方法、ならびに電子タバコ用カートリッジ、電子タバコ | |
JP2020110045A (ja) | 電子タバコ用液体組成物及びそれを有する電子タバコ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230712 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAV | Requested validation state of the european patent: fee paid |
Extension state: TN Effective date: 20230713 Extension state: MA Effective date: 20230713 |